⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DWTX News
Dogwood Therapeutics, Inc. Common Stock
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development
accessnewswire.com
RNAZ
DWTX
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
globenewswire.com
DWTX
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
globenewswire.com
DWTX
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
globenewswire.com
DWTX
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
accessnewswire.com
DWTX
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
accessnewswire.com
DWTX
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
globenewswire.com
DWTX
Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
accessnewswire.com
DWTX
DWTX
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
accessnewswire.com
DWTX
DWTX
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
accessnewswire.com
DWTX
DWTX